However, recent molecular advances have led to the identification of c-KIT as a promising target in OMM, as c-KIT gene alterations have been associated with a frequency of 10–40% in patients with mucosal melanoma, with clinical trials demonstrating the activity of c-KIT inhibitors in the subgroup harboring KIT mutations (26–29). The gene discussed is KIT; the disease is mucosal melanoma.